Home › Encyclopedia › Pentapeptide-18: Research Status and Trial Data
Research / Unapproved

Pentapeptide-18: Research Status and Trial Data

Molecular formulaC29H39N5O7
Molecular weight569.6 g/mol
Registered trials0
PubChem CID10099522

Anyone researching pentapeptide-18 will find it has no approved medical use and no FDA-reviewed label. This overview summarizes what is publicly known about its chemical identity and clinical trial footprint.

Key takeaways

  • Pentapeptide-18 is classified as an unapproved research compound.
  • No FDA label, approved indication, or brand name exists for this compound.
  • Public clinical trial registries show no registered trials for pentapeptide-18.
  • Its molecular formula is C29H39N5O7, with a molecular weight of about 569.6.

What pentapeptide-18 is

Pentapeptide-18 is a synthetic peptide identified by the chemical structure on record under PubChem CID 10099522. It is a five-amino-acid chain with a defined molecular formula and weight, but it does not carry an FDA-approved label. No mechanism of action, drug class, or indication has been established through regulatory review for this compound.

Clinical trial footprint

Public registries list no clinical trials for pentapeptide-18 at this time. There is no trial-based evidence available to describe how this compound behaves in human studies.

FAQ

Is pentapeptide-18 FDA approved?
No. Pentapeptide-18 is an unapproved research compound with no FDA-reviewed label, approved indication, or brand name on record.
What is pentapeptide-18 made of?
It is a synthetic peptide with the molecular formula C29H39N5O7 and a molecular weight of approximately 569.6. Its structure is catalogued under PubChem CID 10099522.
Are there clinical trials studying pentapeptide-18?
Public clinical trial registries currently show no registered trials for pentapeptide-18. As a result, there is no trial-based evidence describing its effects in humans.
What side effects are reported for pentapeptide-18?
No side effect reports are currently available for pentapeptide-18 in public adverse event databases. This reflects a lack of recorded data rather than a confirmed safety profile.
Does pentapeptide-18 have a known mechanism of action?
No mechanism of action has been established through regulatory review, since pentapeptide-18 has no approved label. Any proposed mechanism would be outside confirmed, labeled data.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication. Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.

Sources: PubChem CID 10099522 ClinicalTrials.gov registry search FDA Adverse Event Reporting System (FAERS)

Updated 2026-11-07